Skip to main content
SpringerLink
Log in

Incretin-Targeting Technologies for Type 2 Diabetes

Dipeptidyl Peptidase IV Inhibitors and Glucagon-Like Peptide-1 Analogs

  • Feature
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Novartis. ADA take-homes: Novartis’ Galvus vs Merck’s Januvia. New York: Lehman Brothers Global Equity Research, 2006

    Google Scholar 

  2. Mayday for dual PPAR agonists: once-hyped therapies in their death throes? Pharm Diagn Innovation 2006; 4 (6): 7–10

    Google Scholar 

  3. Januvia and Galvus lead the charge for new diabetes drug class. Scrip 2006; 3166: 20–1

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Incretin-Targeting Technologies for Type 2 Diabetes. Pharmaceutical & Diagnostic Innovation 4, 3–7 (2006). https://doi.org/10.1007/BF03259650

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03259650

Keywords

Search

Navigation